Key facts
- Outlook Therapeutics director Haddadin Yezan Munther bought shares.
- The value of the purchased shares was $24,145.
- The transaction was disclosed in a regulatory filing.
Haddadin Yezan Munther, a director at Outlook Therapeutics, has acquired shares in the company valued at $24,145. This insider transaction was formally reported through a regulatory filing, providing transparency to investors regarding the director's stake in the company. Such filings are standard practice for tracking significant share movements by corporate insiders.